Treprostinil palmitil for pulmonary arterial hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Mar 2026: Trial registered, NCT07481981
  2. 21 Jul 2026: Trial started, NCT07481981

The trials

NCT07481981: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

State
Under way
Phase
Phase 3
People
344 planned
Started
21 Jul 2026
Primary completion
28 Dec 2028
Arms
Treprostinil Palmitil Inhalation Powder
Results
None posted
  1. 19 Mar 2026: Trial registered
  2. 21 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Treprostinil Palmitil Inhalation Powder.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.